<!doctype html>
<html>
  <head>
    <title>SibTech, Inc.</title>
    <link type="text/css" rel="stylesheet" href="/style/default.css"></link>
    <script type="text/javascript">
       
      startList = function() {
        if (document.all&&document.getElementById) {
          navRoot = document.getElementById("menu");
          for (i=0; i<navRoot.childNodes.length; i++) {
            node = navRoot.childNodes[i];
            if (node.nodeName=="LI") {
              node.onmouseover=function() {
                this.className+=" over";
              }
              node.onmouseout=function() {
                this.className=this.className.replace(" over", "");
              }
            }
          }
        }
      }
      window.onload=startList;
       
    </script>
  </head>
  <body>
    <h1 id="title">SibTech, Inc.</h1>
    <div id="shell">
      <div id="head">
        <ul id="menu">
          <li><a href="/about" >About Us</a></li>
          <li><a href="/science" class="dropdown">Our Science</a>
            <ul>
              <li><a href="/platform" >Technology Platform</a></li>
              <li><a href="/publications" >Recent Publications</a></li>
              <li><a href="/posters" >Recent Posters</a></li>
            </ul>
          </li>
          <li><a href="/products" >Products</a></li>
          <li><a href="/conjugates" >Custom Conjugates</a></li>
          <li><a href="/licensing" >Licensing</a></li>
          <li><a href="/contact" >Contact Us</a></li>
        </ul>
        <div id="foot">
          <h2><a name="#">Licensing</a></h2>
          

<p>The following technologies are available for licensing.</p>

<p>Call +1 203-775-5677 or email <a href="mailto:jbacker@sibtech.com">jbacker@sibtech.com</a> for additional information.</p>

<h3 id="i-new-fusion-tag-for-site-specific-conjugation-of-payloads-to-targeting-proteins">I. New fusion tag for site-specific conjugation of payloads to targeting proteins.</h3>

<h4 id="description">Description</h4>

<p>Targeted delivery of therapeutic and diagnostic agents might significantly decrease systemic toxicity, increase efficacy of new and old drugs, support development of personalized medicine, and provide new uses for existing therapeutic proteins. Although many proteins can be used for targeted delivery, random conjugation of a &ldquo;payload&rdquo; to a protein creates heterogeneous products that are not well-suited for development and for regulatory approval. This invention eliminates random conjugation and provides a strategy for development of functionally active, homogeneous protein-based products. In this strategy, a protein is expressed with a humanized 15-aa cysteine-containing tag (Cys-tag), and a payload is site-specifically conjugated to a cysteine residue in Cys-tag via thiol-directed chemistries. Cys-tag is compatible with every protein tested so far, and accommodates payloads as different as drugs, contrast agents, dendrimers, liposomes, and functional proteins.</p>

<h4 id="benefits-and-application">Benefits and Application</h4>

<ul>
<li>Cys-tagged protein can be used for targeted delivery of therapeutic and diagnostic agents, dramatically expanding the field of use for a given protein therapeutic.</li>
<li>Cys-tagged protein can be used in development of protein therapeutics to establish biodistribution and internalization.</li>
<li>Cys-tagged protein can be modified to alter pharmacokinetic via site-specific pegylation.</li>
<li>Cys-tagged protein can be modified to suit specific formulation, for example, slow-release formulations.</li>
<li>Cys-tagged protein can be conjugated to tissue engineering scaffolds, biomedical surfaces, or nanoparticles, providing uniform protein-derivatized constructs.</li>
</ul>

<h4 id="intellectual-property-status">Intellectual Property Status</h4>

<ul>
<li>US patent 7,355,019 B2 issued 04/08/2008.</li>
</ul>

<h4 id="related-publication">Related Publication</h4>

<ul>
<li><a href="/papers/VEGF_BD_Mol_Cancer_Ther.pdf">Mol. Cancer. Ther. 4, 1423-1429, 2005</a></li>
<li><a href="/papers/Blankenberg_2006.pdf">Europ. J. Nucl. Med. Mol. Imag. 33, 841-848, 2006</a></li>
<li><a href="/papers/Wu_2006.pdf">Anti-Cancer Agents Med. Chem. 6, 167-184, 2006</a></li>
<li><a href="/papers/Backer_2006b.pdf">Bioconjugate Chem., 17, 912-919, 2006</a></li>
<li><a href="/papers/Backer_2006a.pdf">Biomaterials 27, 5452-5458, 2006</a></li>
</ul>

<h3 id="ii-novel-agents-for-imaging-receptors-for-vascular-endothelial-growth-factor">II. Novel agents for imaging receptors for vascular endothelial growth factor.</h3>

<h4 id="description-1">Description</h4>

<p>Vascular endothelial growth factor (VEGF) is the key regulator of angiogenesis and overexpressed VEGF receptors play the crucial role in the onset and progression of tumor angiogenesis. receptors are the primary targets of tremendous efforts to develop inhibitors of angiogenesis. However, these receptors are not used as biomarkers for prescribing or monitoring anti-angiogenic therapy due to a lack of methods for assessment of their prevalence. This invention provides molecular probes for PET, SPECT, and NIRF imaging VEGF receptors. The probes are based on a novel single-chain VEGF (scVEGF) expressed with a proprietary cysteine-containing tag for site-specific conjugation of contrast agents. VEGF-based probes bind to and internalized by VEGF receptors as effectively as parental VEGF, providing unique opportunities for non-invasive imaging VEGF receptors in vivo. Information on prevalence of VEGF receptors in patients might lead to evidence-based selection of candidates for anti-angiogenic therapy, facilitate design of personalized treatment regiments, enable early diagnostics and discrimination between benign and malignant lesions.</p>

<h4 id="benefits-and-application-1">Benefits and Application</h4>

<ul>
<li>Clinical development of VEGF based probes for PET imaging will lead to a new diagnostic tool for a wide range of indications.</li>
<li>VEGF-based imaging probes are powerful tools in R&amp;D on drugs affecting vasculature</li>
</ul>

<h4 id="intellectual-property-status-1">Intellectual Property Status</h4>

<ul>
<li>US patent 7,355,019 B2 issued 04/08/2008.</li>
</ul>

<h4 id="related-publication-1">Related Publication</h4>

<ul>
<li>Mol. Cancer. Ther. 4, 1423-1429, 2005</li>
<li>Europ. J. Nucl. Med. Mol. Imag. 33, 841-848, 2006</li>
<li>Nature Med 13, 504-509, 2007</li>
</ul>

<p><br />
<br />
Call +1 203-775-5677 or email <a href="mailto:jbacker@sibtech.com">jbacker@sibtech.com</a> for additional information.</p>

        </div>
      </div>
    </div>
  </body>
</html>
